Teva Pharmaceutical Industries Ltd (NYSE:TEVA)’s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $6.34 and last traded at $6.37, with a volume of 1048412 shares changing hands. The stock had previously closed at $7.04.

TEVA has been the topic of several research reports. BMO Capital Markets decreased their price target on shares of Teva Pharmaceutical Industries from $11.00 to $9.00 and set a “market perform” rating on the stock in a report on Friday, August 9th. Wells Fargo & Co set a $17.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Tuesday, May 28th. Wolfe Research initiated coverage on shares of Teva Pharmaceutical Industries in a report on Friday, July 19th. They set a “peer perform” rating and a $9.00 price target on the stock. Maxim Group reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, May 2nd. Finally, Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Friday, July 5th. Six investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries presently has an average rating of “Hold” and an average price target of $13.21.

The business has a 50-day moving average of $8.25. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.73. The firm has a market cap of $7.14 billion, a price-to-earnings ratio of 2.27, a price-to-earnings-growth ratio of 0.73 and a beta of 1.64.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.02. The firm had revenue of $4.34 billion for the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The company’s revenue for the quarter was down 7.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.78 EPS. On average, equities analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.26 EPS for the current fiscal year.

In other news, Director Sol J. Barer purchased 111,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were purchased at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the transaction, the director now owns 115,942 shares of the company’s stock, valued at $1,041,159.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Notaristefani Carlo De sold 16,070 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the completion of the transaction, the vice president now owns 49,659 shares in the company, valued at approximately $567,105.78. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC increased its stake in shares of Teva Pharmaceutical Industries by 272.6% in the 2nd quarter. Renaissance Technologies LLC now owns 9,786,063 shares of the company’s stock valued at $90,325,000 after acquiring an additional 7,159,900 shares in the last quarter. Camber Capital Management LP increased its stake in shares of Teva Pharmaceutical Industries by 85.7% in the 2nd quarter. Camber Capital Management LP now owns 6,500,000 shares of the company’s stock valued at $59,995,000 after acquiring an additional 3,000,000 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $17,864,000. Strs Ohio increased its stake in shares of Teva Pharmaceutical Industries by 1,909.4% in the 2nd quarter. Strs Ohio now owns 1,651,700 shares of the company’s stock valued at $15,245,000 after acquiring an additional 1,569,500 shares in the last quarter. Finally, Redmile Group LLC increased its stake in shares of Teva Pharmaceutical Industries by 72.1% in the 1st quarter. Redmile Group LLC now owns 3,147,000 shares of the company’s stock valued at $49,345,000 after acquiring an additional 1,318,100 shares in the last quarter. Hedge funds and other institutional investors own 65.28% of the company’s stock.

Teva Pharmaceutical Industries Company Profile (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: What are momentum indicators and what do they show?

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.